Episode 53: A Landmark Year for Alzheimer Disease
Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Anton Porsteinsson, MD.
Karl Doghramji, MD, FAASM, DFAPA
Anton Porsteinsson, MD
Episode 53 of the NeurologyLive® Mind Moments™ podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments™ podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.
Episode 53, "A Landmark Year for Alzheimer Disease," features an exclusive interview with Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program (AD-CARE); William B. and Sheila Konar Professor of Psychiatry, School of Medicine and Dentistry, University of Rochester. He shared his perspective on the progress made in Alzheimer disease in 2021, from the first approval since 2003 to the agents moving through the pipeline and the improved understanding of AD pathology, and offered a look into what the future may hold.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Phase 3 Study of BXCL501 for Agitation in Alzheimer Disease Initiated
- FDA Accepts Ublituximab Biologics License Application for Relapsing MS
EPISODE BREAKDOWN
1:15 – Agents in late-stage development in Alzheimer disease
10:30 – Additional agents with promise in the pipeline
17:00 – Neurology News Minute
21:05 – The next big step forward in Alzheimer
31:10 – Learning from prior failures, improving diagnostics
45:00 – Looking back on the progress in 2021, and ahead to 2022
Click here to subscribe to the Mind Moments™ podcast. Be sure to leave a rating and review for the show. Thanks for listening!
